Roche Invirase/Abbott Norvir combination study shows 99.6% reduction in HIV viral load at six weeks.
ROCHE INVIRASE/ABBOTT NORVIR COMBO THERAPY SIX-WEEK DATA show a reduction of 99.6% in viral load from early results presented July 11 at the International Conference on AIDS in Vancouver. The study, funded by both companies, is the first to test two protease inhibitors in combination and without nucleoside analogs.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth